Skip to main content
. Author manuscript; available in PMC: 2018 Feb 12.
Published in final edited form as: Nature. 2017 Mar 22;543(7647):723–727. doi: 10.1038/nature21433

Fig. 2. Characterization of lymphoma-specific MHC-I and MHC-II epitopes and somatic mutations.

Fig. 2

(a) B-cell receptor pathway components presented by >50% of patients in the context of MHC-I (pink), MHC-II (blue), or both (red). (b) Nonsynonymous somatic mutations, predicted neoantigens, and the degree of somatic hypermutation in IGVH or IGJH are depicted, along with genes recurrently mutated in the cohort by exome sequencing. (c) Antigen presentation of mutated genes across the cohort. Nested ovals depict increasing evidence levels for candidate neoantigens, starting with nonsynonymous mutations (outermost oval) to direct evidence of neoantigen presentation (innermost oval). (d) TP53- or CCND1-derived MHC-I peptides and observed somatic mutations are depicted in relation to the corresponding protein domains.